Literature DB >> 17576043

Postmenopausal HRT and tibolone in relation to muscle strength and body composition.

D E Jacobsen1, M M Samson, S Kezic, H J J Verhaar.   

Abstract

OBJECTIVES: Sarcopenia, the loss of muscle mass with age, has a great impact on physical function, and especially in postmenopausal women, who experience a greater decline in muscle strength than do men of similar age. Conventional hormone replacement therapy (HRT) may diminish this loss of muscle strength and may even increase muscle strength. However, HRT is not currently promoted for this indication because of its negative side effects, which is why tibolone, a synthetic steroid with oestrogenic, progestogenic, and androgenic activity, may be an alternative option. The aim of this article was to review data on the effect of HRT and tibolone on muscle strength and body composition in postmenopausal women.
METHODS: Medline, Pubmed, Embase, and Sumsearch were searched for articles on the effect of HRT and tibolone on muscle strength and body composition, using the Mesh terms hormone replacement therapy and clinical trial combined with muscle strength or body composition. Tibolone was added as search term with clinical trial and muscle strength or body composition.
RESULTS: Three of five randomized controlled trials reported a significant positive effect of HRT on muscle strength but not on body composition. Tibolone significantly increased handgrip strength and isometric knee extension strength in one randomized placebo-controlled, double-blind trial and increased mean knee extensor strength in one cross-sectional study. Tibolone also increased the lean body mass and decreased the accumulation of body fat.
CONCLUSIONS: HRT and tibolone increase muscle strength. Unlike HRT, tibolone also increases lean body mass and significantly reduces the total body fat content. Further research is recommended to determine whether tibolone is a safe treatment for sarcopenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576043     DOI: 10.1016/j.maturitas.2007.04.012

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  16 in total

Review 1.  How to assess functional status: a new muscle quality index.

Authors:  S Barbat-Artigas; Y Rolland; M Zamboni; M Aubertin-Leheudre
Journal:  J Nutr Health Aging       Date:  2012-01       Impact factor: 4.075

Review 2.  Hormone therapy and skeletal muscle strength: a meta-analysis.

Authors:  Sarah M Greising; Kristen A Baltgalvis; Dawn A Lowe; Gordon L Warren
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-06-26       Impact factor: 6.053

Review 3.  Validated treatments and therapeutic perspectives regarding physical activities.

Authors:  Y Rolland; F Pillard
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

4.  Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO.

Authors:  L Vignozzi; N Malavolta; P Villa; G Mangili; S Migliaccio; S Lello
Journal:  J Endocrinol Invest       Date:  2018-11-19       Impact factor: 4.256

5.  Hormone therapy improves femur geometry among ethnically diverse postmenopausal participants in the Women's Health Initiative hormone intervention trials.

Authors:  Zhao Chen; Thomas J Beck; Jane A Cauley; Cora E Lewis; Andrea LaCroix; Tamsen Bassford; Guanglin Wu; Duane Sherrill; Scott Going
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

6.  The effects of tibolone in older postmenopausal women.

Authors:  Steven R Cummings; Bruce Ettinger; Pierre D Delmas; Peter Kenemans; Victoria Stathopoulos; Pierre Verweij; Mirjam Mol-Arts; Lenus Kloosterboer; Lori Mosca; Claus Christiansen; John Bilezikian; Eduardo Mario Kerzberg; Susan Johnson; Jose Zanchetta; Diederich E Grobbee; Wilfried Seifert; Richard Eastell
Journal:  N Engl J Med       Date:  2008-08-14       Impact factor: 91.245

7.  Comparison of dietary conjugated linoleic acid with safflower oil on body composition in obese postmenopausal women with type 2 diabetes mellitus.

Authors:  Leigh E Norris; Angela L Collene; Michelle L Asp; Jason C Hsu; Li-Fen Liu; Julia R Richardson; Dongmei Li; Doris Bell; Kwame Osei; Rebecca D Jackson; Martha A Belury
Journal:  Am J Clin Nutr       Date:  2009-06-17       Impact factor: 7.045

Review 8.  Frailty, osteoporosis and hip fracture: causes, consequences and therapeutic perspectives.

Authors:  Y Rolland; G Abellan van Kan; A Bénétos; H Blain; M Bonnefoy; P Chassagne; C Jeandel; M Laroche; F Nourhashémi; P Orcel; F Piette; C Ribot; P Ritz; C Roux; J Taillandier; F Trémollières; G Weryha; B Vellas
Journal:  J Nutr Health Aging       Date:  2008-05       Impact factor: 4.075

Review 9.  Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives.

Authors:  Y Rolland; S Czerwinski; G Abellan Van Kan; J E Morley; M Cesari; G Onder; J Woo; R Baumgartner; F Pillard; Y Boirie; W M C Chumlea; B Vellas
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

10.  Carla Task Force on Sarcopenia: propositions for clinical trials.

Authors:  G Abellan van Kan; E André; H A Bischoff Ferrari; Y Boirie; G Onder; M Pahor; P Ritz; Y Rolland; C Sampaio; S Studenski; M Visser; B Vellas
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.